Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) reported Q4 Revenue for the quarter at $69.55 million versus the consensus estimate of $67.72 million.

GUIDANCE:

Mirum Pharmaceuticals, Inc. sees FY2024 revenue of $310-320 million, versus the consensus of $316.4 million.

For earnings history and earnings-related data on Mirum Pharmaceuticals, Inc. (MIRM) click here.